Back to Journals » Drug Design, Development and Therapy » Volume 4

Original Research

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

      
Total article views   HTML views PDF downloads Totals
17,503 Dovepress* 15,837+ 2,033 17,870
PubMed Central* 1,666 619 2,285
Totals 17,503 2,652 20,155
*Since 15 November 2010
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
8 0 0 0 0 8

View citations on PubMed Central and Google Scholar